Once-daily treatment for canine atopic dermatitis
Delivers 6-in-1 parasite protection for cats
Valuable discounts, expert information, and tips
See how injectable medications offer value beyond the prescription
The first and only FDA-Approved veterinary antiemetic
The first long-lasting monoclonal antibody therapy for canine atopic dermatitis
Vaccination for the prevention of respiratory disease caused by BRSV
The beef industry’s No. 1 branded preconditioning program
Exclusive pricing program for Cattle producers
Outstanding protection against costly respiratory and reproductive diseases
Treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Innovative food safety products that help deliver a farm-to-fork solution for beef
The most comprehensive guarantee available
First and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses
Annual vaccination with CORE EQ INNOVATOR helps provide the protection your horse needs
Treats and controls encysted small strongyles, bots and roundworms. QUEST PLUS contains an additional active ingredient for efficacy against tapeworms
Patented and scientific method of determining fair service pricing to improve your clinic's profitability
Connect directly to valuable dairy management resources and experts
The most "veterinarian recommended" and "producer used" prostaglandin in the market
Delivers the peace of mind and profitability that come with no milk discard
Effective and convenient treatment for acute metritis in cattle
Working together to improve reproduction
One injection treats and controls swine respiratory disease for 7 days
Protect sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas
The industry standard for in ovo technology.
Full automation solutions for hatchery automation
Prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry
for the prevention of coccidiosis in poultry
modified-live vaccine that helps poultry companies reduce their overall Salmonella load
Blood glucose monitoring system
Smart new diagnostics platform that can reinvent your in-house diagnostic routines
Detect Johne’s Disease with confidence in cattle and goat herds
Simple and effective detection of a deadly Feline Virus
Accurate, affordable and easy to use
Order Beef Genetics products online
Order Dairy Genetics products online
Delivers reliable predictions of genetic merit based on test results of core traits
Represents the latest advancement in Angus genotyping technology.
Register today to learn more
Become a more effective leader
Looking for a tailored experience?
Earn continuing education credits and stay current on industry developments with Zoetis’ convenient, on-demand learning solutions.
Veterinarians, Veterinarian Techs, Business Owners, and Farm Hands
Launch your veterinary career
Veterinarian Students and Recent Graduates
Animal health expertise and results-focused resources for high-performing teams and leaders.
Veterinarians, Dairy producers, Beef producers, Equine Specialists, Pork producers, Poultry producers, Managers, Business Owners and Staff
Home / Products / Cats & Dogs / Sileo / Pharmacology
You will now receive email updates from Zoetis Inc.
SILEO® (dexmedetomidine oromucosal gel) is presented in a 3 mL oral syringe that can be redosed, as needed. SILEO provides a low dose of dexmedetomidine, which calms but does not sedate the dog. The dog remains fully functional while the undesirable behaviors of noise aversion are eliminated or minimized.
Since dexmedetomidine is absorbed through the mucous membranes, SILEO in an oromucosal gel formulation provides a convenient mode of administration for pet owners to use at home.
Bioavailability: Oral transmucosal (OTM) administration achieves the optimum effect.
Onset of Action: The calming effects of SILEO can be observed shortly after administration—OTM administration reaches peak plasma concentration within 0.6 hours.
Intensity of Effect: With the 28 percent OTM bioavailability, peak plasma concentration is approximately ¼ of the same dosage with IV or IM administration. This means that about ¼ of the dose of dexmedetomidine administered is absorbed. As a result, there is a dose-dependent effect on behavioral and physiological responses.
Duration of Effect: The half-life of SILEO is 0.5–3h; therefore, SILEO has a duration of effect of 2–3 hours.
Noise aversion is a neurologic condition. It starts in the locus coeruleus, a cluster of noradrenergic nuclei in the brainstem, where norepinephrine is the main neurotransmitter.
The locus coeruleus and norepinephrine (LC-NE) facilitate the physiological and behavioral responses to stress, fear and anxiety, typically manifesting as fight, flight or avoidance (freezing behavior). Under normal circumstances, the response to acute stress is short-lived: all systems return back to normal when the threat subsides due to autoregulatory mechanisms. However, repeated exposure to acute traumatic stress causes repeated activation of the LC-NE system, which can lead to the development of anxiety.9 The fear and anxiety associated with noise aversion is an example of a repeated traumatic stressor of the sympathetic system.6 Therefore, using a pharmacological agent that decreases the LC-NE system is a logical approach for noise aversion.
The anxiolytic effect of SILEO is mediated through the locus coeruleus. Dexmedetomidine, the active substance of SILEO, is a highly potent and selective alpha-2 adrenoceptor agonist.
Dexmedetomidine binds with the alpha-2 receptors in the locus coeruleus, preventing release of norepinephrine and reducing levels of norepinephrine in the LC-NE neural pathways. Reduced levels of norepinephrine reduce the levels of anxiety and fear.
The same dosage of dexmedetomidine in a different formulation and different mode of administration produces different effects.
The dosage of SILEO is the same as the pre-anesthetic dose of DEXDOMITOR® (dexmedetomidine), but formulation and route are different, resulting in different effects on heart rate and sedation.
This graph compares the mean sedation scores of SILEO in telemerized laboratory Beagles administered SILEO oral transmucosally compared to DEXDOMITOR administered intramuscularly, both at the 125 mcg/m2 dosage.
The effect of SILEO on client-owned dogs was evaluated in a placebo-controlled study conducted at veterinary clinics. Heart rates were taken before and after treatment: Heart rates dropped slightly for the SILEO-treated dogs, but remained within normal range. The average heart rate for the SILEO-treated dogs was 98 bpm compared to 115 bpm for the placebo group.
Important Safety Information: SILEO Do not use SILEO in dogs with severe cardiovascular disease, respiratory, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue or in dogs hypersensitive to dexmedetomidine or to any of the excipients. SILEO should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. Do not use in dogs sedated from previous dosing. SILEO has not been evaluated in dogs younger than 16 weeks of age or in dogs with dental or gingival disease that could have an effect on the absorption of SILEO. SILEO has not been evaluated for use in breeding, pregnant, or lactating dogs or for aversion behaviors to thunderstorms. Transient pale mucous membranes at the site of application may occur with SILEO use. Other uncommon adverse reactions included emesis, drowsiness or sedation. Handlers should avoid direct exposure of SILEO to their skin, eyes or mouth. Failure to lock the ring-stop on the syringe before dosing SILEO could potentially lead to an accidental overdose. Always review INSTRUCTIONS FOR USE before dispensing and dosing. See full Prescribing Information. DEXDOMITOR and DEXDOMITOR 0.1 Do not use DEXDOMITOR or DEXDOMITOR 0.1 in dogs or cats, and ANTISEDAN in dogs, with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue. DEXDOMITOR and DEXDOMITOR 0.1 should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. As with all α2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists with DEXDOMITOR and DEXDOMITOR 0.1. The use of DEXDOMITOR and DEXDOMITOR 0.1 as a preanesthetic in dogs and cats significantly reduces the amount of induction and maintenance anesthetic requirements. Careful patient monitoring is necessary to avoid anesthetic overdose. Arrhythmias, bradycardia, apnea, emesis, convulsions, hypersalivation may occur with DEXDOMITOR and DEXDOMITOR 0.1 use. Severe dyspnea and respiratory crackles due to acute or delayed pulmonary edema could develop in cats. DEXDOMITOR and DEXDOMITOR 0.1 have not been evaluated for use in breeding, pregnant, or lactating dogs or cats; in dogs younger than 16 weeks of age or in cats younger than 12 weeks of age; or in geriatric dogs or cats. Occasional vomiting may occur with ANTISEDAN use. Rarely, a brief state of excitement or apprehensiveness may be seen in ANTISEDAN-treated dogs. Other potential side effects of α2-antagonists, such as ANTISEDAN, include hypersalivation, diarrhea, and tremors. See full Prescribing Information.
Mon–Fri, 8am–8pm ET
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2017 Zoetis Services LLC. All rights reserved.